reference/4079791

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/4079791

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
issn	1478-6354 1478-6362
issueIdentifier	1
pageRange	78-
publicationName	Arthritis Research & Therapy
startingPage	78
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_2897889ea18249f8d56e85c26d8bc7d4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c9715a34c9ccde7ccc72cadee3277b94 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_7842d4a3c63f3eec2ded513ced2c398f
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_58dd47f6ae5145f7f3f5225754a4fd7e
bibliographicCitation	Neogi T, Hunter DJ, Churchill M, Shirinsky I, White A, Guermazi A, Omata M, Fountaine RJ, Pixton G, Viktrup L, Brown MT, West CR, Verburg KM. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study. Arthritis Research & Therapy. 2022 Mar 29;24(1):78. doi: 10.1186/s13075-022-02759-0.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_489a510a2d7afa8df54d9ea38778eba4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d9b6fa2f1813e5a3bf070da4d21813ad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f6aed20e8cc2ac7dc77f06a070a948f0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4cb7376ae1003fdf410b78f32d4f7c21 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1e068ea59bdd2c2e457c3bfbb963706c http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9515-1711 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0fadb7cba793b39034d30cfbaa4f456 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bfc8fc9a5b8e2d1475c0f2bab274bf1b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8ecbf7dbca3bee4b99fe14311722cc55 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_75c56fb8913f9ee9c4abd7bb0e74b8ef http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fe647d0c682c49e4c682173c0d803704 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ee17f12d8510c7ef6b52fc0bb6ce6677 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a2692d9291f8b3d220f50785264135ca
date	2022-03-29^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC8966257 https://pubmed.ncbi.nlm.nih.gov/35351194 https://doi.org/10.1186/s13075-022-02759-0
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/30289 https://portal.issn.org/resource/ISSN/1478-6354 https://portal.issn.org/resource/ISSN/1478-6362
language	English
source	https://scigraph.springernature.com/ https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study
discusses	http://id.nlm.nih.gov/mesh/M0001335 http://id.nlm.nih.gov/mesh/M0546449 http://id.nlm.nih.gov/mesh/M0556300
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D015207Q000188 http://id.nlm.nih.gov/mesh/D020370Q000188 http://id.nlm.nih.gov/mesh/D020370Q000150
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D010147Q000379 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D000894Q000627
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3033 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID156391 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2662 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8722 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8756 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b7472e8eaaedddca9eebb75ec5d929ed

Showing number of triples: 1 to 56 of 56.